Natera, Inc. (NTRA) company profile
Close on Nov 17, 2026Market cap $41.44BP/E –Yield –
About Natera
Services-Medical Laboratories, SIC 8071
The company is a diagnostics provider specializing in cell-free DNA molecular assays and bioinformatics algorithms across oncology, women's health, and organ health. In oncology, it offers tests for molecular residual disease detection, recurrence monitoring, and therapy selection, serving oncology clinics, cancer researchers, and biopharmaceutical partners. In women's health, its portfolio includes non-invasive prenatal screening, carrier screening, and pregnancy loss evaluation. In organ health, it supplies tests to detect transplant rejection in heart, lung, and kidney recipients, as well as genetic panels for chronic kidney disease. It also licenses its cloud bioinformatics platform to external clinical laboratories.
The company is headquartered in Austin, Texas, with additional laboratory facilities in San Carlos, California, and Boulder, Colorado. Its commercial presence spans more than 80 countries globally through direct sales engagement and a network of over 100 laboratory and distribution partners.
Summary of the business section of Natera's latest annual report, written by StockData.
Company profile
Company
- Legal name
- Natera, Inc.
- Founded
- 2009
- Headquarters
- Austin, TX
- Address
- 13011 Mccallen Pass, Building A Suite 100 78753
- Phone
- (650) 249-9090
- Website
- www.natera.com
- Employees
- 6,140, Dec 31, 2025
- Industry
- Services-Medical Laboratories
- Incorporated in
- Delaware
- Fiscal year ends
- December 31
- Auditor
- Ernst & Young LLP, San Jose, California
Stock & identifiers
- Ticker
- NTRA
- Exchange
- Nasdaq
- IPO date
- Jul 2, 2015
- Shares outstanding
- 144M, Jul 31, 2026
- Public float
- $21.83B, Jun 30, 2025
- Filer category
- Large accelerated filer
- SEC CIK
- 1604821
- CUSIP
- 632307104
- ISIN
- US6323071042
- FIGI
- BBG001J1BQ86
- Share class FIGI
- BBG001V0FSF8
- LEI
- 529900CQ3OZ0A0VYVU59
- EIN
- 01-0894487
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| Matthew Rabinowitz | EXECUTIVE CHAIRMAN, Director | 2,116,928 |
| Steven Leonard Chapman | CEO AND PRESIDENT, Director | 87,431 |
| Daniel Rabinowitz | SEC. AND CHIEF LEGAL OFFICER | 167,880 |
| John Fesko | PRESIDENT, CHIEF BUS. OFFICER | 195,276 |
| Solomon Moshkevich | PRESIDENT, CLINICALDIAGNOSTICS | 101,323 |
| Michael Burkes Brophy | CHIEF FINANCIAL OFFICER | 45,779 |
| Jonathan Sheena | Director | 229,462 |
| Rowan E. Chapman | Director | 4,663 |
| Eric H. Rubin | Director | 2,204 |
| Roelof Botha | Director | 1,080,663 |
| Roy D. Baynes | Director | 20,083 |
| Thomas J. Lynch Jr. | Director | 1,905 |
| Herm Rosenman | Director | 5,821 |
| Gail Boxer Marcus | Director | 7,852 |
| Monica Bertagnolli | Director | 6,945 |
| Brinkley Ruth Williams | Director | 5,475 |
| James Healy | Director | 1,596,540 |
CEO pay and shareholder return
Pay versus performance table from the proxy statement
| Fiscal year | CEO total pay | CEO pay actually paid | Other executives (avg) | Value of $100 invested | Peer group |
|---|---|---|---|---|---|
| FY2025 | $14.96M | $60.79M | $6.79M | $230 | $125 |
| FY2024 | $13.03M | $95.39M | $6.12M | $159 | $93 |
| FY2023 | $12.73M | $32.77M | $4.88M | $63 | $94 |
| FY2022 | $8.25M | -$10.48M | $4.55M | $40 | $90 |
| FY2021 | $23.34M | $17.84M | $8.42M | $94 | $100 |
| FY2020 | $8.08M | $60.87M | $2.80M | $295 | $126 |
“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.
Executive compensation, fiscal 2025
Summary compensation table from the latest proxy statement
| Executive | Salary | Stock awards | Incentive pay | Other | Total | vs. prior year |
|---|---|---|---|---|---|---|
| Steven Chapman Chief Executive Officer and President | $853.71K | $12.98M | $1.11M | $9.90K | $14.96M | +15% |
| Michael Brophy Chief Financial Officer | $562.79K | $4.50M | $390.18K | $6.21K | $5.46M | +12% |
| John Fesko President, Chief Business Officer | $504.65K | $4.19M | $351.60K | $9.90K | $5.05M | +3% |
| Solomon Moshkevich President, Clinical Diagnostics | $504.65K | $4.50M | $351.60K | $9.90K | $5.37M | +10% |
| Matthew Rabinowitz Executive Chairman | $426.43K | $10.38M | $473.51K | – | $11.28M | +15% |
Stock and option awards are grant-date fair values, not realized pay. “Other” includes pension value changes and all other compensation. Source proxy statement.
IPO
From the final prospectus (Form 424B4) and the first day of trading
Offering
- Type
- Initial public offering
- Final prospectus filed
- Jul 2, 2015
- Offer price
- $18.00
- Securities offered
- 10,000,000
- Gross proceeds
- $180.00M
- Exchange
- Nasdaq
- First trading day
- Jul 1, 2015
- First-day close
- $18.000.0%
- Lock-up ends (est.)
- Dec 28, 2015
“The initial public offering price of our common stock is $18.00 per share.”
Lock-up end is estimated as 180 days after the first trading day; the prospectus sets the actual terms.
Employees
Headcount reported in annual reports
“As of December 31, 2025, our global workforce comprised 6,140 employees, of whom 6,135 were full time employees.”
Corporate history
Events identified from SEC filings
| Date | Event | Details |
|---|---|---|
| Jul 2, 2015 | IPO | Initial public offering priced (424B4 prospectus) |
| Jun 26, 2015 | Listing | Registration of securities on an exchange (Form 8-A) |
See a number that looks wrong?